Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Investor Presentation (July 2022)
18 slides from Immunovia Ab's investor presentation, July 2022
Slide 1: Corporate Presentation
Corporate Presentation July 2022 Confidential not for distribution
Slide 2: Forward looking statements
Forward looking statements • IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectivel
Slide 3: Revolutionizing blood-based diagnostics to advance early detection of pancreatic cancer
Revolutionizing blood-based diagnostics to advance early § detection of pancreatic cancer and increase patient survival rates 2021-09-24 Confidential not for distribution 3
Slide 4: Company overview
Company overview Front-runner in non-invasive early detection Initial ~1.7-1.8 million US patient population in of pancreatic cancer (PDAC) pancreatic cancer Revolutionizing blood-based Commercial build out in US following launch in Incorporated 2007 in Sweden, 2017 in US diagnostics to August 2021
Slide 5: Pancreatic is one of the most lethal cancers with limited diagnostic innovation
Pancreatic is one of the most lethal cancers with limited diagnostic innovation US deaths by cancer 2020 5-year survival rates: Lung 138,225 22.8% Colorectum 54,443 65.1% Pancreas 47,638 11.5% Breast 42,617 90.6% Prostate 32,428 96.8% Liver 31,078 20.8% Non-Hodgkin lymphona 20,858 73.8% Brain, centr
Slide 6: Patients are often diagnosed too late when surgery is no longer an option
Patients are often diagnosed too late when surgery is no longer an option 42% <20% Early Dx 80% Late Dx 3% 5-year survival rate 5-year survival rate when diagnosed early when found late (surgical optionality) (metastatic, non-resectable) Treatment methods: Treatment methods: • Chemotherapy • Chemoth
Slide 7: US patient population of approximately 1.7 to 1.8 million
US patient population of approximately 1.7 to 1.8 million First risk group 315,000 – 350,000 individuals that need 1-2 Familial/Hereditary commercialized in US, tests per year August 2021 ~1.7-1.8 million • High-risk individuals typically identified by gastroenterologist or oncologist Patients treat
Slide 8: Limitations in current standard of care for pancreatic cancer diagnosis
Limitations in current standard of care for pancreatic cancer diagnosis Imaging frequently fails Too few patients under Imaging is burdensome Imaging results can be to identify pancreatic surveillance for patients inconclusive cancer early • Only 21% of patients who • Both MRCP and • Small tumors ar
Slide 9: Revolutionary blood-based test: IMMray PanCan-d
Revolutionary blood-based test: IMMray® PanCan-d First-to-market First US blood-based advantage pancreatic cancer monitoring test Accurate microarray Unique “disease fingerprints” patented technology from a blood sample Significant unmet US addressable market size medical need of ~1.7-1.8 million pa
Slide 10: IMMray PanCan-d provides specific, actionable results
IMMray® PanCan-d provides specific, actionable results Immunovia Medical HIGH-RISK SIGNATURE Director calls ordering Serum is classified as high-risk for pancreatic cancer PRESENT physician; prompt clinical evaluation NEGATIVE FOR Continue with regular Serum is classified as low-risk for pancreatic
Slide 11: Broad clinical validation of IMMray PanCan-d
Broad clinical validation of IMMray® PanCan-d Blinded validation study Commercial test model study Verification study (Publication: Clin Transl Gastroenterol. 2022) 2020 2020 2022 PDAC stage I-II versus healthy PDAC stage I-II versus healthy PDAC stage I-II versus familial/hereditary 1,113 patient s
Slide 12: Outstanding performance compared to standard methods
Outstanding performance compared to standard methods Diagnostic Performance for Detecting PDAC I – IV 100% 98-99% 90% 92% 93% 91% 89% 86% 80% 70% 60% 50% IMMray PanCan-d EUS MRI Sensitivity Specificity IMMray® PanCan-d shows comparable sensitivity and superior specificity to imaging and is less burd
Slide 13: Extensive key opinion leader & advocacy network
Extensive key opinion leader & advocacy network Advocacy Partner Organizations Key Research and Clinical Collaborators Commercial strategy leverages KOL relationships and patient advocacy collaborations 13
Slide 14: Staged approach to commercializing IMMray PanCan-d
Staged approach to commercializing IMMray PanCan-d PHASE LAUNCH (CURRENT) GROWTH (MEDIUM-TERM) EXPANSION (LONG-TERM) Genetic and familial risk factors Intended Uses in Cysts Genetic and familial risk factors Pancreatic Cancer Genetic and familial risk factors Cysts (potential) Chronic pancreatitis D
Slide 15: Financial highlights & planned investments
Financial highlights & planned investments Key Investments next 24 months Target growth capital • Build out field and inside sales teams Investment 24-Month Use of Proceeds • Invest in digital marketing and advocacy R&D $8M (27%) partnerships to drive patient demand Commercial $15M (50%) • Scale ope
Slide 16: Establishing the leader in the early detection of pancreatic cancer
Establishing the leader in the early detection of pancreatic cancer AREA ACCOMPLISHMENTS – MILESTONES - NEXT 18 MONTHS OPERATIONAL First to market dedicated liquid biopsy test for the early Build out sales team to enable nationwide coverage detection of pancreatic cancer in the US Explore pote
Slide 17: Experienced global management team
Experienced global management team Philipp Mathieu Karin Almqvist Jeff Borcherding Linda Mellby Thomas King Group CEO & Liwendahl US CEO, VP R&D US Medical Director President Group CFO US Commercial Lead Collective Experience – Broader Management Team Appointed several experienced key leaders for gr
Slide 18: Q&A
18 Q&A helloir@immunovia.com www.immunovia.com 2021-09-24 Confidential not for distribution 18